US FDA approves Roche's breast cancer drug
June 8 |
June 8 (Reuters) - U.S. health regulators have approved a new breast cancer drug from Roche Holding AG that the company hopes will become the standard treatment for women with an aggressive, incurable form of cancer.
The Food and Drug Administration on Friday approved the injectable drug Perjeta for women with a type of breast cancer known as HER-2 positive, which makes up about a quarter of all breast cancers and has no cure.
- Tweet this
- Link this
- Share this
- Digg this
- Reprints
We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/
Comments (1)
12346 wrote:
FDA knows that all forms of cancer cures that work have been available for 100 years. One Canadian Dr. announced a cure three years ago but, big Pharma would not support it as they could not make money. If you want to know the truth do some reserach. Start with the DVD Healing Cancer for inside out. There are many more. If you think the FDA is on your side=no way.
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.
Follow Reuters